Cost of Wegovy, Zepbound, Ozempic, and Mounjaro: What You Actually Pay in 2025

Why These Drugs Cost So Much

Brand GLP-1 and dual GIP/GLP-1 receptor agonists carry high list prices because of the manufacturing complexity behind peptide synthesis, the multi-year Phase 3 programs required for FDA approval, and the absence of direct generic competition. Novo Nordisk set Wegovy's wholesale acquisition cost at approximately $1,349 per month in 2025, while Eli Lilly priced Zepbound at approximately $1,059. Neither figure represents what most patients pay at the pharmacy counter, but they are the baseline from which insurer negotiations and out-of-pocket costs are calculated.

The clinical justification for that price is real. In STEP-1 (N=1,961), once-weekly subcutaneous semaglutide 2.4 mg produced a mean body weight reduction of 14.9% at 68 weeks versus 2.4% with placebo (P<0.001), the largest weight-loss signal ever seen from a single pharmacological agent in a randomized controlled trial at the time of publication [1]. Then SURMOUNT-1 (N=2,539) showed tirzepatide 15 mg achieving a mean weight loss of 20.9% at 72 weeks compared to 3.1% with placebo (P<0.001), raising the bar further [2]. Outcomes of that magnitude have historically appeared only after bariatric surgery.

The SELECT cardiovascular outcomes trial (N=17,604) added another layer of justification. Semaglutide 2.4 mg reduced the rate of major adverse cardiovascular events by 20% versus placebo over a mean follow-up of 34.2 months in adults with overweight or obesity and pre-existing cardiovascular disease but without diabetes [3]. Payers who previously viewed these agents as "lifestyle drugs" are being pressured to reconsider.

Still, list price does not equal patient cost. The sections below break down what you actually pay depending on your insurance situation, the brand you're prescribed, and whether you use a compounded alternative.

Wegovy Cost: List Price, Insurance, and Savings Programs

Wegovy (semaglutide 2.4 mg, Novo Nordisk) carries a 2025 U.S. list price of approximately $1,349 per month for four auto-injector pens. That figure applies to the maintenance dose; during the 16-week dose-escalation phase (starting at 0.25 mg), the monthly pen count is the same but dose-strength differs.

With commercial insurance: Coverage is inconsistent. Most commercial plans cover Wegovy only if the patient meets specific BMI thresholds and has at least one weight-related comorbidity. The Wegovy FDA label specifies approved use in adults with a BMI of 30 or greater, or a BMI of 27 or greater with at least one weight-related condition such as type 2 diabetes, hypertension, or dyslipidemia [4]. Patients who meet those criteria and whose plan covers anti-obesity medication may pay $0 to $200 monthly depending on formulary tier.

Novo NovoCare Savings Card: Commercially insured patients who are eligible may pay as little as $25 per month through the NovoCare savings program. The card does not apply to patients with Medicare, Medicaid, or other federally funded coverage.

Without insurance: Cash-pay patients can use NovoCare's direct-pay option, which listed at approximately $499 per month as of early 2025 for qualifying patients, a significant reduction from the wholesale acquisition cost but still a substantial expense.

Medicare and Medicaid: Medicare Part D is barred by statute from covering drugs approved solely for weight management. As of 2025, that prohibition has not been lifted by federal legislation, though the Treat and Reduce Obesity Act has been reintroduced in multiple Congressional sessions. Medicaid coverage varies by state; some state Medicaid programs have added coverage for at least one anti-obesity GLP-1.

STEP-5 (N=304) extended the efficacy picture to 104 weeks, showing that patients maintaining semaglutide 2.4 mg sustained a mean weight reduction of 15.2% from baseline, suggesting that ongoing monthly expenditure corresponds to durable benefit [5].

Zepbound Cost: The Newer Tirzepatide Option

Zepbound (tirzepatide, Eli Lilly) received FDA approval for chronic weight management in November 2023 and carries a 2025 list price of approximately $1,059 per month for four auto-injector pens at any dose level, making it modestly cheaper on list price than Wegovy.

LillyDirect Cash-Pay Program: Eli Lilly sells Zepbound directly to patients through LillyDirect at a self-pay price of approximately $349 per month for the 2.5 mg or 5 mg doses, and approximately $499 per month for the 7.5 mg, 10 mg, 12.5 mg, or 15 mg doses as of mid-2025. These single-dose vials ship to the patient's door. That program does not involve insurance billing.

Lilly Savings Card: Commercially insured patients may pay as little as $25 per month with the Lilly Savings Card, subject to eligibility exclusions for federal-program beneficiaries.

The efficacy data supporting that cost is substantial. SURMOUNT-1 showed that tirzepatide 15 mg produced a 20.9% mean weight reduction at 72 weeks [2]. SURMOUNT-4 (N=670) demonstrated that discontinuing tirzepatide after 36 weeks led to a 14.8% weight regain over the subsequent 52 weeks compared to only 1.8% in the continuation group (P<0.001), confirming that this is a chronic-use medication [6]. Patients and prescribers should budget accordingly.

The Zepbound FDA label approves use in adults with BMI of 30 or greater, or BMI of 27 or greater with at least one weight-related comorbidity [7]. That mirrors the Wegovy label and the criteria used by AACE/ACE obesity clinical practice guidelines for pharmacotherapy initiation [8].

Ozempic Cost: The Diabetes Label at a Lower Price Point

Ozempic (semaglutide, Novo Nordisk) is FDA-approved for type 2 diabetes and cardiovascular risk reduction, not for weight management. Its 2025 list price is approximately $968 per month for one multi-dose pen (delivering four weekly doses). That is lower than Wegovy's list price despite containing the same active molecule, because Ozempic's maximum approved dose (2.0 mg) sits below Wegovy's weight-management dose (2.4 mg).

Insurance coverage: Commercial insurers and Part D plans cover Ozempic broadly for type 2 diabetes. Patients with T2D and a legitimate diabetes diagnosis may have copays as low as $10 to $50 monthly with formulary coverage.

Off-label use: Prescribing Ozempic off-label for weight management in patients without diabetes is legal but creates insurance friction. Most commercial plans will deny weight-management claims filed under the diabetes drug, and NovoCare savings-card programs for Ozempic specify diabetes diagnoses.

STEP-2 (N=1,210) evaluated semaglutide 1.0 mg in adults with T2D and overweight or obesity and found a 9.6% mean body weight reduction at 68 weeks [9]. STEP-8 (N=338) compared semaglutide 2.4 mg head-to-head against liraglutide 3.0 mg (Saxenda) and showed a 15.8% mean weight loss with semaglutide versus 6.4% with liraglutide over 68 weeks (P<0.001) [10].

The practical upshot: Ozempic may be the most accessible brand GLP-1 cost-wise for patients with T2D who also want metabolic weight benefits, but it is not the correct prescription for patients whose primary diagnosis is obesity without diabetes.

Mounjaro Cost: Tirzepatide for Diabetes

Mounjaro (tirzepatide, Eli Lilly) shares its active ingredient with Zepbound. The difference is indication. Mounjaro is approved for type 2 diabetes management, while Zepbound is approved for chronic weight management. The 2025 list price for Mounjaro is approximately $1,069 per month for four auto-injector pens.

Insurance coverage: Like Ozempic, Mounjaro is broadly covered by commercial insurance and Part D plans for T2D. Out-of-pocket costs with insurance can range from $25 to $100 monthly depending on formulary tier.

Lilly Savings Card (Mounjaro): Eligible commercially insured patients may pay as little as $25 per month. A separate savings program has offered cash-pay patients a reduced price, though amounts change periodically.

SURMOUNT-2 (N=938) studied tirzepatide in adults with T2D and found mean weight reductions of 13.9% (10 mg) and 15.7% (15 mg) at 72 weeks versus 3.3% with placebo (P<0.001) [11]. Patients with T2D who need both glucose control and meaningful weight loss have strong clinical rationale to ask their prescriber about Mounjaro specifically.

Compounded Semaglutide and Tirzepatide Cost

During FDA-declared drug shortage periods, licensed 503A compounding pharmacies may prepare semaglutide and tirzepatide base or salt forms for individual patients. Compounded GLP-1 products from telehealth platforms and compounding pharmacies have typically priced between $199 and $499 per month in 2025, a fraction of brand list prices.

The cost difference is real. So are the regulatory caveats. The FDA does not approve compounded drugs. The agency issued guidance in 2024 stating that compounded semaglutide is not FDA-approved and carries risks including dosing errors, contamination, and variable potency. As of early 2025, the FDA removed semaglutide from the drug shortage list, which means 503A pharmacies are no longer supposed to compound it for the general patient population; only 503B outsourcing facilities may compound under specific conditions for office use.

The HealthRX clinical team uses the following four-factor framework to guide patients evaluating compounded GLP-1 options:

1. Shortage status: Is the branded drug currently on the FDA shortage list? If not, compounding from a 503A pharmacy falls outside the legal exemption.
2. Pharmacy credentialing: Is the pharmacy licensed in your state, PCAB-accredited, and willing to share a Certificate of Analysis for each batch?
3. Prescriber oversight: Will a licensed provider review labs, monitor for adverse effects, and adjust dosing on a defined schedule?
4. Cost vs. risk calculus: Does the monthly savings justify the absence of FDA-reviewed manufacturing controls for your specific risk profile?

Patients who cannot afford brand GLP-1s and are not on Medicare should first exhaust the LillyDirect self-pay vials, NovoCare direct-pay programs, and any state pharmaceutical assistance programs before pursuing compounded alternatives.

How Insurance Coverage Actually Works (and Where It Breaks Down)

Insurance coverage for these agents is fragmented in ways that frustrate patients and prescribers alike. The core problem is that many commercial plans treat obesity as a lifestyle condition rather than a chronic disease, despite the American Association of Clinical Endocrinology defining obesity as "a complex, chronic, relapsing, multifactorial, neurobehavioral disease" in its 2016 clinical practice guidelines [8].

Employer-sponsored plans are the most variable. Large self-insured employers set their own formularies. Some Fortune 500 companies added GLP-1 weight-management coverage between 2023 and 2025; others removed it after seeing cost projections. Patients on these plans need to call the pharmacy benefits number on their insurance card and ask specifically about the formulary tier for the NDC (National Drug Code) of the exact drug they're prescribed.

ACA Marketplace plans are required to cover preventive services with an A or B rating from the USPSTF, but anti-obesity medications have not uniformly been assigned that rating for all patient populations. Intensive behavioral counseling for obesity has a B rating, which means some plans must cover that but not the drug.

Medicare Part D cannot by statute cover drugs approved solely for weight management. Wegovy's recent cardiovascular indication (based on SELECT trial data) may create a limited coverage pathway for patients with cardiovascular disease, but as of mid-2025 that pathway remains inconsistently implemented across Part D plans.

Prior authorization applies to nearly every brand GLP-1 regardless of plan type. Required documentation typically includes BMI, list of comorbidities, evidence of prior diet and exercise interventions, and sometimes a documented failure of a lower-cost drug such as orlistat or phentermine-topiramate.

STEP-3 (N=611) showed that semaglutide 2.4 mg combined with intensive behavioral therapy produced a mean 16.0% weight loss at 68 weeks versus 5.7% with intensive behavioral therapy plus placebo (P<0.001) [12]. That finding is clinically relevant to prior authorization submissions: documenting a structured behavioral intervention alongside the drug request strengthens the case and aligns with what payers want to see.

Side-by-Side Cost Comparison: 2025 Numbers

| Drug | Active Ingredient | FDA Indication | Approx. List Price/Month | LillyDirect or NovoCare Self-Pay | Savings Card Min (Insured) | |---|---|---|---|---|---| | Wegovy | Semaglutide 2.4 mg | Chronic weight management | $1,349 | ~$499 (NovoCare) | $25 | | Ozempic | Semaglutide up to 2.0 mg | Type 2 diabetes / CV risk | $968 | ~$199-$299 (NovoCare programs vary) | $25 | | Zepbound | Tirzepatide | Chronic weight management | $1,059 | $349-$499 (LillyDirect) | $25 | | Mounjaro | Tirzepatide | Type 2 diabetes | $1,069 | Variable (Lilly) | $25 | | Compounded semaglutide | Semaglutide base/salt | N/A (not FDA-approved) | N/A | $199-$499 (telehealth) | N/A | | Compounded tirzepatide | Tirzepatide base/salt | N/A (not FDA-approved) | N/A | $199-$499 (telehealth) | N/A |

Prices reflect 2025 published or reported figures and may change. Always verify current pricing at the time of prescription.

Long-Term Cost Considerations

These drugs are not short courses. SURMOUNT-4 showed 14.8% weight regain within 52 weeks of stopping tirzepatide [6]. STEP-5 showed maintained 15.2% weight loss over 104 weeks of continuous semaglutide use [5]. The clinical picture is consistent: discontinuation leads to weight regain in most patients.

At $1,349 per month for Wegovy, a two-year course costs approximately $32,376 at list price. At $499 per month through NovoCare's direct-pay option, that drops to $11,976. At $349 per month via LillyDirect for Zepbound maintenance dosing, two years runs $8,376. None of these figures account for the downstream cost offsets from reduced cardiovascular events, fewer diabetes medications, lower blood pressure prescriptions, or reduced joint-replacement surgeries, which health economists continue to model.

Dr. Louis Aronne, Director of the Comprehensive Weight Control Center at Weill Cornell Medicine, has stated in peer-reviewed commentary that "treating obesity as a chronic disease requires the same long-term pharmacotherapy commitment we accept for hypertension or hyperlipidemia." That framing directly challenges the one-year coverage limits many plans impose.

Practical Steps to Reduce Your Out-of-Pocket GLP-1 Cost

Getting from list price to an affordable monthly number requires working several systems in parallel. Start with these six steps:

1. Confirm your exact insurance formulary status for the specific NDC you're prescribed. The same drug at a different dose strength may be on a different tier.
2. Apply for the manufacturer savings card before filling your first prescription. Novo NovoCare and Lilly's savings programs process applications online in minutes.
3. Ask your prescriber to document BMI, comorbidities, and any prior weight-management attempts in the prior authorization letter. Specificity accelerates approval.
4. If your plan denies coverage, file a formal appeal within 30 days. Denials are reversed at a meaningful rate when supported by physician documentation and clinical trial data.
5. Consider LillyDirect self-pay vials for Zepbound if you are uninsured or underinsured and your provider has confirmed the appropriate dose range. The per-vial pricing can be significantly lower than list.
6. Request a referral to a registered dietitian for concurrent behavioral therapy. STEP-3 showed additive weight-loss benefit [12], and behavioral counseling is covered by most plans, reducing the total burden placed on the drug alone.

Patients with T2D who are prescribed Ozempic or Mounjaro for their primary diabetes indication often find coverage far smoother than those seeking Wegovy or Zepbound for weight management. If you have both conditions, your prescriber should document the diabetes indication prominently.